Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) EBT Margin (2020 - 2023)

Gain Therapeutics (GANX) has 4 years of EBT Margin data on record, last reported at 9279.8% in Q1 2023.

  • For Q1 2023, EBT Margin fell 201195.0% year-over-year to 9279.8%; the TTM value through Dec 2023 reached 40735.22%, down 4062383.0%, while the annual FY2023 figure was 40735.22%, 4061756.0% down from the prior year.
  • EBT Margin reached 9279.8% in Q1 2023 per GANX's latest filing, down from 5337.72% in the prior quarter.
  • Across five years, EBT Margin topped out at 36019.29% in Q4 2021 and bottomed at 46440.84% in Q1 2021.
  • Average EBT Margin over 4 years is 7366.71%, with a median of 8453.7% recorded in 2020.
  • Peak YoY movement for EBT Margin: plummeted -3770533bps in 2021, then soared 3917300bps in 2022.
  • A 4-year view of EBT Margin shows it stood at 14134.15% in 2020, then surged by 155bps to 36019.29% in 2021, then plummeted by -115bps to 5337.72% in 2022, then tumbled by -74bps to 9279.8% in 2023.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 9279.8% in Q1 2023, 5337.72% in Q2 2022, and 7267.84% in Q1 2022.